Northeast Financial Consultants Inc Takes $2.40 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Share on StockTwits

Northeast Financial Consultants Inc purchased a new position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 177,455 shares of the biotechnology company’s stock, valued at approximately $2,401,000.

A number of other large investors have also recently made changes to their positions in IRWD. Gotham Asset Management LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at about $135,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at about $190,000. Financial Counselors Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at about $204,000. Bank of Montreal Can grew its stake in shares of Ironwood Pharmaceuticals by 426.9% in the fourth quarter. Bank of Montreal Can now owns 16,846 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 13,649 shares in the last quarter. Finally, Perennial Advisors LLC purchased a new position in Ironwood Pharmaceuticals in the first quarter valued at about $243,000. Institutional investors own 99.22% of the company’s stock.

IRWD traded down $0.29 on Wednesday, reaching $10.83. The company’s stock had a trading volume of 13,747 shares, compared to its average volume of 1,475,839. Ironwood Pharmaceuticals, Inc. has a 1 year low of $9.07 and a 1 year high of $21.20. The company has a market capitalization of $1.71 billion, a P/E ratio of -11.38 and a beta of 1.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.10). The business had revenue of $68.73 million during the quarter, compared to the consensus estimate of $81.93 million. During the same quarter in the previous year, the company posted ($0.25) earnings per share. The firm’s revenue was down .6% compared to the same quarter last year. Sell-side analysts anticipate that Ironwood Pharmaceuticals, Inc. will post -0.11 earnings per share for the current year.

In other Ironwood Pharmaceuticals news, CFO Gina Consylman sold 4,055 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $10.53, for a total transaction of $42,699.15. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 5.90% of the company’s stock.

A number of brokerages recently commented on IRWD. BidaskClub downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Credit Suisse Group set a $16.00 price target on Ironwood Pharmaceuticals and gave the company a “hold” rating in a report on Friday, March 22nd. ValuEngine raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 13th. BTIG Research set a $19.00 price target on Ironwood Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 14th. Finally, GMP Securities raised Ironwood Pharmaceuticals from a “sell” rating to a “neutral” rating and increased their price target for the company from $11.50 to $14.00 in a report on Monday, February 25th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $15.15.

TRADEMARK VIOLATION WARNING: “Northeast Financial Consultants Inc Takes $2.40 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)” was posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://weekherald.com/2019/06/12/northeast-financial-consultants-inc-takes-2-40-million-position-in-ironwood-pharmaceuticals-inc-nasdaqirwd.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

See Also: What is the significance of a dead cat bounce?

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.